The third study found that the Prolaris score compared to other clinical variables was the strongest predictor of metastatic disease in men who underwent prostatectomy. Patients with a high Prolaris score had a six-fold higher risk of developing metastases compared with patients with a low score. These results confirm that using Prolaris at the time of diagnosis can help determine which patients are at highest risk of metastasis so that treatment decisions can be made based on personal risk profiles.
Three new studies of Prolaris, a prognostic molecular test for risk stratification in prostate cancer, were presented at the American Urological Association (AUA) Annual Meeting in Orlando, Florida.
Prolaris is a molecular diagnostic test that measures the level of RNA expression of genes involved in prostate tumor growth. This helps physicians stratify the risk of disease progression in patients with prostate cancer. Low levels of gene expression are associated with a low risk of disease progression and men in this group may be candidates for active surveillance. High levels of gene expression are associated with a higher risk of disease progression and these patients may benefit from additional therapy.
The first study followed 761 patients whose prostate cancer was diagnosed by needle biopsy and treated with conservative therapy. The primary end point was death from prostate cancer and the median follow-up time was 9.5 years. A patient’s risk of dying from prostate cancer doubled with each unit increase in the Prolaris score.